Literature DB >> 3835825

Biochemical mechanisms of resistance to tiazofurin.

H N Jayaram.   

Abstract

The purpose of this investigation was to examine factors which regulate the reprogramming of gene expression in tumors responsible for resistance to tiazofurin. To study the resistance phenomenon drug-induced tumor lines were selected and examined for the mechanism of resistance. A comparison of the biochemical expression of resistance to tiazofurin in drug-induced resistant lines of hepatoma 3924A, leukemias L1210 and P388 revealed that the 3 lines expressed similar genetic alterations related to reduced TAD content, decreased NAD pyrophosphorylase activity and increased synthesis of guanylates from salvaging preformed guanine indicating that these 3 factors play an important role in the resistance to tiazofurin. Resistance was stable in the leukemia lines and did not require drug to maintain resistance. Hepatoma 3924A resistant line reverted to sensitive state in the absence of drug selection pressure. NAD pyrophosphorylase activity was substantially deleted in the tiazofurin resistant leukemia lines, but was only significantly decreased in the hepatoma resistant line. Extensive biochemical alterations including enhanced activity of IMP dehydrogenase, increased inosinate and guanylate pools, and reduced uptake of tiazofurin were found in the hepatoma line resistant to tiazofurin. To examine the applicability of these results to naturally sensitive and spontaneously resistant tumors, murine tumors were examined. In murine tumors, TAD accumulation, ratios of enzyme activities responsible for the synthesis and degradation of TAD, and the ratios of perturbation of inosinate and guanylate pools following tiazofurin challenge demonstrated significant correlation with the sensitive or resistant nature of the tumors. To extrapolate these observations to human tumor systems, cytotoxicity of tiazofurin and its metabolic effects were compared in 6 human lung cancer cell lines derived from cancer patients with small cell lung cancer (4 lines) and lung adenocarcinoma (2 lines). Cell lines exhibiting greater sensitivity to tiazofurin accumulated significantly larger amounts of TAD and showed significant reduction of guanylate pools following tiazofurin incubation. The activity of the enzyme responsible for the formation of TAD, NAD pyrophosphorylase, did not correlate with responsiveness to tiazofurin but the enzyme which hydrolyzes TAD, TADase, correlated positively with the status of resistance.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3835825     DOI: 10.1016/0065-2571(85)90070-6

Source DB:  PubMed          Journal:  Adv Enzyme Regul        ISSN: 0065-2571


  6 in total

Review 1.  Clinical toxicity associated with tiazofurin.

Authors:  J L Grem; L Rubinstein; S A King; B D Cheson; M J Hawkins; D D Shoemaker
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

Review 2.  The NAD metabolome--a key determinant of cancer cell biology.

Authors:  Alberto Chiarugi; Christian Dölle; Roberta Felici; Mathias Ziegler
Journal:  Nat Rev Cancer       Date:  2012-09-28       Impact factor: 60.716

Review 3.  Role of differentiation induction in action of purine antimetabolites.

Authors:  G Weber; Y Hata; N Prajda
Journal:  Pharm World Sci       Date:  1994-04-15

4.  Studies of purine and tiazofurin metabolism in drug sensitive human chronic myelogenous leukemia K 562 cells.

Authors:  K Pillwein; H N Jayaram; G Weber
Journal:  Blut       Date:  1988-08

5.  Mechanism and control of degradation and resynthesis of adenylates in tumour cells.

Authors:  Z Kovacević; O Brkljac; D Jerance
Journal:  Biochem J       Date:  1991-01-15       Impact factor: 3.857

Review 6.  Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story.

Authors:  Rand Naffouje; Punita Grover; Hongyang Yu; Arun Sendilnathan; Kara Wolfe; Nazanin Majd; Eric P Smith; Koh Takeuchi; Toshiya Senda; Satoshi Kofuji; Atsuo T Sasaki
Journal:  Cancers (Basel)       Date:  2019-09-11       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.